Oxford trial tests old drug to boost lung cancer treatment
NCT ID NCT04648033
Summary
This early-stage trial tested whether adding an existing drug called atovaquone to standard chemo-radiation could make treatment more effective for advanced lung cancer. The study involved 21 patients to find the safest dose of atovaquone when combined with standard treatment. Researchers specifically wanted to see if atovaquone could reduce low-oxygen areas in tumors, which are known to resist radiation therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Churchill Hospital, Oxford University Hospitals
Oxford, OX3 7LE, United Kingdom
-
Guy's and St Thomas'
London, SE1 9RT, United Kingdom
-
Western General Hospital, NHS Lothian
Edinburgh, EH4 2XU, United Kingdom
Conditions
Explore the condition pages connected to this study.